Bioclinica, ArisGlobal partner to 'transform drug safety model'

Tablets production

Bioclinica has teamed up with ArisGlobal and its safety cloud platform to help the CRO run its drug safety monitoring services.

In a statement, the Newtown, PA-based CRO said that a “top 20 pharmaceutical company” has already selected Bioclinica to standardize its safety case processing service on the ArisGlobal platform, while two other companies are said to be making the switch from competing platforms.

Under this partnership, Bioclinica also becomes the preferred partner for Fort Lauderdale, FL-based ArisGlobal in business process consulting and change management as sponsors implement or upgrade its drug safety software, ARISg. 

“Early adoption speaks to the strength and value of our joint solution in addressing industry’s long-wanted desire for such a safety offering,” said Bioclinica's president of eHealth solutions, Mukhtar Ahmed.

ArisGlobal’s VP of safety George Philips added: “Through our partnership with Bioclinica, we are able to provide the pharmaceutical industry with an unprecedented level of streamlined and cost efficient end-to-end pharmacovigilance services. By utilizing these services, resources within an organization can now be shifted to address other pressing needs.”

ArisGlobal and Bioclinica’s Safety and Regulatory Solutions division (formerly known as Synowledge) said the deal was made in order to “deliver cost-effective and regulatory compliant services.”

Ahmed added that: “The formation of this partnership addresses the full continuum of pharmacovigilance as a service. Together Bioclinica and ArisGlobal provide the most comprehensive solution, whether an organization wants to handle safety internally or outsource it to our team of safety experts.”

Bioclinica has signed a number of deals in the past 18 months, including most recently a new tie-up with Japanese CRO EPS to focus on risk-based monitoring in clinical trials--one of 6 new deals and pacts the company has made since 2014.  

In February, it also launched a new internal “Post-Approval Research” division as it looks to take big steps into the growing realm of helping biopharma with data and costs after launch.

- check out the release